PRECAUTIONSGeneralButalbital, acetaminophen, and caffeine tablets should be
prescribed with caution in certain special-risk patients, such as the elderly or
debilitated, and those with severe impairment of renal or hepatic function, or
acute abdominal conditions.
Information for PatientsButalbital, Acetaminophen, and Caffeine Tablets USP may impair
mental and/or physical abilities required for the performance of potentially
hazardous tasks such as driving a car or operating machinery. Such tasks should
be avoided while taking this product.
Alcohol and other CNS depressants may produce an additive CNS depression when
taken with Butalbital, Acetaminophen, and Caffeine Tablets USP, and should be
avoided.
Butalbital may be habit-forming. Patients should take the drug only for as
long as it is prescribed, in the amounts prescribed, and no more frequently than
prescribed.
For information on use in geriatric patients, see PRECAUTIONS/Geriatric
Use.
Laboratory TestsIn patients with severe hepatic or renal disease, effects of
therapy should be monitored with serial liver and/or renal function tests.
Drug InteractionsThe CNS effects of butalbital may be enhanced by monoamine
oxidase (MAO) inhibitors.
Butalbital, acetaminophen, and caffeine may enhance the effects of: other
narcotic analgesics, alcohol, general anesthetics, tranquilizers such as
chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing
increased CNS depression.
Drug/Laboratory Test
InteractionsAcetaminophen may produce false-positive test results for urinary
5-hydroxyindoleacetic acid.
Carcinogenesis, Mutagenesis,
Impairment of FertilityNo adequate studies have been conducted in animals to determine
whether acetaminophen or butalbital have a potential for carcinogenesis,
mutagenesis or impairment of fertility.
Pregnancy
Teratogenic
EffectsPregnancy Category C: Animal
reproduction studies have not been conducted with Butalbital, Acetaminophen, and
Caffeine Tablets USP. It is also not known whether butalbital, acetaminophen,
and caffeine can cause fetal harm when administered to a pregnant woman or can
affect reproduction capacity. This product should be given to a pregnant woman
only when clearly needed.
Nonteratogenic
EffectsWithdrawal seizures were reported in a two-day-old male infant
whose mother had taken a butalbital-containing drug during the last two months
of pregnancy. Butalbital was found in the infant’s serum. The infant was given
phenobarbital 5 mg/kg, which was tapered without further seizure or other
withdrawal symptoms.
Nursing MothersCaffeine, barbiturates, and acetaminophen are excreted in breast
milk in small amounts, but the significance of their effects on nursing infants
is not known. Because of potential for serious adverse reactions in nursing
infants from butalbital, acetaminophen, and caffeine, a decision should be made
whether to discontinue nursing or to discontinue the drug, taking into account
the importance of the drug to the mother.
Pediatric UseSafety and effectiveness in pediatric patients below the age of
12 have not been established.
Geriatric UseClinical studies of Butalbital, Acetaminophen, and Caffeine
Tablets USP did not include sufficient numbers of subjects aged 65 and over to
determine whether they respond differently from younger subjects. Other reported
clinical experience has not identified differences in responses between the
elderly and younger patients. In general, dose selection for an elderly patient
should be cautious, usually starting at the low end of the dosing range,
reflecting the greater frequency of decreased hepatic, renal, or cardiac
function, and of concomitant disease or other drug therapy.
Butalbital is known to be substantially excreted by the kidney, and the risk
of toxic reactions to this drug may be greater in patients with impaired renal
function. Because elderly patients are more likely to have decreased renal
function, care should be taken in dose selection, and it may be useful to
monitor renal function.